Filing Details
- Accession Number:
- 0001209191-21-055438
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-09-10 16:14:56
- Reporting Period:
- 2021-09-09
- Accepted Time:
- 2021-09-10 16:14:56
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1699382 | Pmv Pharmaceuticals Inc. | PMVP | Pharmaceutical Preparations (2834) | 463218129 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1825216 | Leila Alland | C/O Pmv Pharmaceuticals, Inc. 8 Clarke Drive, Suite 3 Cranbury NJ 08512 | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2021-09-09 | 100 | $3.90 | 100 | No | 4 | M | Direct | |
Common Stock | Disposition | 2021-09-09 | 100 | $30.25 | 0 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Employee Stock Option (right to buy) | Disposition | 2021-09-09 | 100 | $0.00 | 100 | $3.90 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
353,850 | 2030-02-04 | No | 4 | M | Direct |
Footnotes
- The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 30, 2020.
- One-fourth of the shares subject to the option vested on December 3, 2020, and one forty-eighth of the shares subject to the option shall vest each month thereafter.